Navigation Links
New gene therapy proves promising as hemophilia treatment
Date:12/11/2013

CHAPEL HILL, N.C. Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia A, a serious and costly bleeding condition that affects about 50,000 people in the United States and millions more around the world.

Before the gene treatment, the animals experienced about five serious bleeding events a year. After receiving the novel gene therapy, though, they experienced substantially fewer bleeding events over three years, as reported in the journal Nature Communications.

"The promise and the hope for gene therapy is that people with hemophilia would be given a single therapeutic injection and then would express the protein they are missing for an extended period of time, ideally for years or even their entire lifetimes," said Tim Nichols, director of the Francis Owen Blood Research Laboratory at UNC and co-author of the paper. The hope is that after successful gene therapy, people with hemophilia would experience far fewer bleeding events because their blood would clot better.

People with hemophilia A lack the coagulation factor VIII in their blood plasma the liquid in which red, white, and platelet cells are suspended.

"Bleeding events in hemophilia are severe, and without prompt factor VIII replacement, the disease can be crippling or fatal," said Nichols, a professor of medicine and pathology. "The random and spontaneous nature of the bleeding is a major challenge for people with hemophilia and their families."

In underdeveloped countries, people with hemophilia and many undiagnosed people typically die from bleeding in their late teens or early 20s. In developed countries, patients usually live fairly normal lives, as long as they receive preventive injections of recombinant protein therapy a few times a week. The disease requires life-long management that is not without health risks. The annual cost of medications alone is about $200,000 a year.

However, about 35 percent of people with hemophilia A develop an antibody response that blocks the factor VIII therapy. They require continuous infusions of various protein factors and they face a higher mortality rate. Also, the cost of treatment can easily rise to $2 million or more a year per patient.

Nichols and David Wilcox from the Medical College of Wisconsin figured out a potential way around the antibody response in dogs with naturally occurring hemophilia A.

Using a plasmapheresis machine and a blood-enrichment technique, the research team isolated specific platelet precursor cells from three dogs that have hemophilia A. The team then engineered those platelet precursor cells to incorporate a gene therapy vector that expresses factor VIII. The researchers put those engineered platelet precursors back into the dogs. As the cells proliferated and produced new platelets, more and more were found to express factor VIII.

Then, nature took over. Platelets naturally discharge their contents at sites of vascular injury and bleeding. In this experiment, the contents included factor VIII.

In the 2 1/2 years since the dogs received the gene therapy, researchers found that factor VIII was still being expressed in platelets that were coursing throughout the vascular systems of all three dogs. All three experienced much less bleeding. In the dog that expressed the most factor VIII in platelets, the bleeding was limited to just one serious event each year over the course of three years. And such bleeding events were easily treatable with current standard therapies.

"This has been very successful," Nichols said. "And now we want to explore the possibility of moving it into human clinical trials for people with hemophilia A, similar to what Paul Monahan and Jude Samulski at UNC are currently doing for people with hemophilia B, which is a deficiency of factor IX."

If approved, the platelet-targeted therapy would likely be restricted to patients who develop the antibody that stifles factor VIII therapy through normal injections. But as the gene therapy is refined, it could become a viable option for people with blood disorders who don't have inhibitory antibodies.


'/>"/>

Contact: Mark Derewicz
mark.derewicz@unch.unc.edu
919-923-0959
University of North Carolina Health Care
Source:Eurekalert  

Related biology news :

1. How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy?
2. T cell immunotherapy: Promising results in children and adults with leukemia
3. International gene therapy trial for bubble boy disease shows promising early results
4. Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy
5. Top 12 Pioneer Awards for seminal work in gene and cell therapy selected by blue ribbon panel
6. Hormone therapy could enhance the therapeutic effect of head and facial bone grafts
7. BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy
8. No evidence to support stem cell therapy for pediatric optic nerve hypoplasia
9. Largest therapy trial worldwide: Psychotherapy treats anorexia effectively
10. Biological therapy with cediranib improves survival in women with recurrent ovarian cancer
11. Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New gene therapy proves promising as hemophilia treatment
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
Breaking Biology News(10 mins):
(Date:3/30/2017)... 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... agreements with Nippon Shinyaku, Co., Ltd. for Defitelio ® ... daunorubicin liposome injection), or CPX-351, in Japan ... agreements, Nippon Shinyaku will receive exclusive rights to develop ... in return for an upfront payment to ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Crohn’s & Colitis ... inflammatory bowel diseases (IBD), and ReachMD , the nation’s largest medical education ... learners. , The partnership, which launched in the fall of 2016, includes ...
(Date:3/29/2017)... 29, 2017 "Surging application of gesture control ... government are expected to drive the growth of gesture ... recognition market is expected to be worth USD 18.98 ... between 2017 and 2022. The touchless sensing market is ... growing at a CAGR of 17.44% between 2017 and ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Nerium International Mexico has been approved as an active member of the ... and protection among distributers and consumers in relationship marketing. This professional organization fosters ...
Breaking Biology Technology: